Portfolio company
Grey Wolf Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
Grey Wolf Therapeutics develops antigen modulation treatments targeting cancer and autoimmune disorders to help the immune system recognise and destroy diseased cells.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
T-Therapeutics
The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.
Adaptam Therapeutics
Adaptam Therapeutics develops antibody-based therapies for solid tumours to treat oncology patients by targeting immunosuppressive myeloid cells.
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
NovalGen
NovalGen develops multi-specific antibody therapies and self-regulating immunotherapies for patients with oncology, autoimmune, haematological, and metabolic disorders.
Pandion Therapeutics
The company develops bispecific antibody therapeutics for patients with autoimmune diseases, inflammatory conditions and organ transplants to achieve localised immunomodulation.
Alyssum Therapeutics
This company develops B cell-based targeted immunotherapies for patients with solid tumours and complex immunological conditions.
Apitope
Apitope develops antigen-specific peptide therapeutics to treat autoimmune diseases and allergies for patients requiring targeted immunotherapy and immune tolerance restoration.
Mozart Therapeutics
The company develops CD8 T regulatory cell modulators to treat patients with autoimmune and inflammatory diseases including type 1 diabetes.